Psilocybin Therapy Shows Promise for Millions with Depression

Pending FDA approval, psilocybin-assisted therapy could offer a new treatment avenue for those with major depressive disorder and treatment-resistant depression.

• Research indicates that psilocybin therapy might benefit between 2.2 to 5.6 million Americans currently undergoing treatment for major depression.
• Psilocybin, found in magic mushrooms, is fast-tracked by the FDA due to its potential as a breakthrough therapy for depression.
• Study estimates suggest 24% to 62% of depression patients could qualify for psilocybin treatment, depending on applied safety criteria.
• Significant infrastructure and policy adjustments are needed to accommodate potential demand if the therapy receives FDA approval.
• Insurance coverage, particularly Medicaid, will play a critical role in determining access to psilocybin therapy for lower-income individuals.

3 Articles

Neuroscience News Study Finds Technology Networks